Clinical Trials Directory

Trials / Completed

CompletedNCT02976792

Effectiveness of the NephroCheck™ After TAVI

Effectiveness of the NephroCheck™ to Predict Postoperative Acute Kidney Injury in Patients Undergoing a Transcatheter Aortic Valve Implantation

Status
Completed
Phase
Study type
Observational
Enrollment
62 (actual)
Sponsor
University Hospital, Bordeaux · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Postoperative acute renal failure is a frequent complication after a Transcatheter Aortic Valve Implantation (TAVI). The current practice cannot predict Acute Kidney Injuries (AKI) early enough to prevent an organic dysfunction triggering, consequently, cortical tubular necrosis. Several recent studies in cardiac surgery have shown that sonographic criteria, the Renal Resistive Index (IRR), and a urinary biomarker, the NephroCheck™, could predict AKI promptly. These markers, sonographic and biologic, have both the advantage to be non-invasive and easy to perform. Each marker seems to have sensitivity and specificity to predict AKI promptly after cardiac surgery. Therefore, the IRR and the NephroCheck™ test could become essential tests to guide clinicians in determining rapidly whether a patient will develop AKI after a TAVI procedure. However, so far, no study has tested the NephroCheck™ in patients undergoing TAVI. Therefore, the aim of this prospective observational study will be first to determine the effectiveness of the NephroCheck™ to predict AKI at an early stage after a TAVI procedure. The secondary outcome will be to compare the NephroCheck™ with the RRI in predicting at an earlier stage than the traditional method an AKI.

Conditions

Interventions

TypeNameDescription
PROCEDURERenal Resistive Index/NephroCheck™testRenal Resistive Index and NephroCheck™ test before TAVI and after TAVI

Timeline

Start date
2016-09-01
Primary completion
2017-02-01
Completion
2017-02-01
First posted
2016-11-29
Last updated
2024-05-16

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02976792. Inclusion in this directory is not an endorsement.